Vascular Diseases
7 cases on [genuine one-line description of what this topic's real clinical territory covers] — choose a case below to open its full multi-voice debate.
Dana has already tried — and refused to repeat — one prostacyclin delivery route for her escalating PAH. Whether that counts as the pathway failing, or only one route within it, decides whether sotatercept or an untried oral agent comes next.
Diagnosed today at the highest risk tier PAH offers, Marcus's team must decide whether sotatercept belongs in his very first regimen or whether he first needs the background therapy every sotatercept trial assumed patients already had.
Louise's pulmonary hypertension is more severe than her lung disease alone would predict. Whether a pulmonary vasodilator helps her turns on where her resistance sits against a specific trial threshold, not on delivery route.
Walter's new PAH diagnosis calls for upfront combination therapy by every guideline measure, except that the trial establishing it was never tested in a 74-year-old already running his blood pressure this low.
Priya's pulmonary embolism has left her right ventricle strained and her troponin elevated, but her blood pressure has never wavered. Whether that stability is reassuring or just not yet informative is what the team actually disagrees about.
Samuel's lungs are hemorrhaging faster than his team can be certain which antibody is driving it. Plasma exchange's value may hinge on a second serology result still a day away.
Frank's chronic clot sits too distal for surgery to reach. Whether medication and a catheter procedure compete for the same slot in his treatment, or actually work in sequence, is what divides the room.